Beyond Development: Using Continuous Manufacturing To Accelerate OSD Commercialization

Continuous manufacturing is no longer simply a technical ambition — it’s a strategic approach to advancing oral solid dose (OSD) therapies toward commercialization. When combined with Real-Time Release Testing (RTRT), continuous manufacturing can deliver meaningful advantages in speed, scalability, quality, and manufacturing efficiency while reducing the complexity traditionally associated with scale-up.

In this webinar, Douglas B. Hausner, Ph.D., senior manager of continuous manufacturing at Thermo Fisher Scientific, shares firsthand insights from supporting the company’s first OSD product submission enabled by continuous manufacturing and RTRT. Filed across major global markets, including the US and EU, the submission offers valuable perspective on applying these technologies from late-stage development through commercialization.

Key takeaways include how continuous manufacturing and RTRT supported a successful global regulatory submission, the potential of these approaches to accelerate development timelines and enhance product quality, and the strategic value of integrating continuous processes and RTRT earlier in development. Drawing on lessons learned from Phase III through commercial launch, Hausner also shares practical insights to help inform your own continuous manufacturing strategy.